Jemperli, a cancer drug manufactured by GlaxoSmithKline, improved survival for patients diagnosed with a form of uterine cancer by more than one year, the British drugmaker said Saturday, ...

Women in England with a specific type of endometrial cancer will be able to access an immunotherapy for the first time, after NICE backed use of GlaxoSmithKline's PD-1 inhibitor Jemperli via the ...

Jemperli works by attaching itself to a protein on specific immune system cells, called T cells. This helps the T cells work better to find cancer cells and kill them, which slows or stops the ...

Jemperli (dostarlimab-gxly) is a brand-name injection that’s prescribed for certain types of cancers in adults. As with other drugs, Jemperli can cause side effects, such as diarrhea, anemia ...

GSK Plc’s Jemperli helped extend the lives of patients with endometrial cancer in a late-stage test, suggesting the medicine could become the top seller the UK drugmaker is predicting.

PHILADELPHIA, August 01, 2024--Expanded approval of Jemperli (dostarlimab-gxly) plus chemo in endometrial cancer as first & only IO-based treatment to show overall survival benefit ...

Oct 30 (Reuters) - British drugmaker GSK , opens new tab said on Monday its cancer drug Jemperli when combined with chemotherapy, met the primary goal of overall survival in patients with advanced ...

Jemperli in combination with chemotherapy is the first immuno-oncology treatment approved in the frontline setting for this patient population in Singapore.[1,2] Latest published local registry ...

Jemperli is a prescription drug used to treat certain cancers, including endometrial cancer. Learn about the drug's side effects and how to manage them.

For Jemperli overall, GSK expects its PD-1 latecomer could reach more than £2 billion peak sales. The British pharma is exploring various combinations, including with TIGIT and its newly licensed ...

Jemperli is a prescription drug used to treat certain types of endometrial cancer. Learn about its cost, ways to find savings, and more.

Jemperli was approved for similar expanded use in endometrial cancer in the United States in August 2024. The drug is also ...